Skip to main content

Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia

Clinical Drug Investigation volume 40, pages 1167–1176 (2020)Cite this article

Abstract

Background and Objective

In the REFLECT trial, lenvatinib showed superior clinical benefits to sorafenib in terms of progression-free survival and was non-inferior for overall survival in the treatment of advanced hepatocellular carcinoma (HCC). We assessed the cost-effectiveness of lenvatinib compared with sorafenib for patients with advanced HCC in Australia.

Method

A partitioned-survival model was built to perform a cost-effectiveness analysis comparing lenvatinib and sorafenib from an Australian health-system perspective. Survival curves were obtained from the REFLECT trial and fitted with parametric survival functions for extrapolation purposes beyond the trial follow-up. Cost and quality-adjusted life-years (QALYs) were accrued over the 10-year time horizon of the model. Deterministic and probability sensitivity analysis (PSA) were carried out to verify the validity of the model.

Results

Lenvatinib incurred higher costs (A$96,325) and superior health outcomes (QALYs: 1.205), while sorafenib had lower costs (A$92,394) and inferior health outcomes (QALYs: 1.086). Thus, lenvatinib yielded an incremental cost-utility ratio of A$33,028/QALY gained. Further, the results of the PSA found that the probability of lenvatinib being cost-effective at a willingness-to-pay threshold of A$50,000/QALY was 64%.

Conclusion

Our study found that, at current prices, lenvatinib is a cost-effective treatment option compared with sorafenib for the first-line treatment of patients with advanced HCC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  2. Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982–2014: increasing incidence and improving survival. Liver Int. 2019;39(3):522–30. https://doi.org/10.1111/liv.13966.

    CAS  Article  PubMed  Google Scholar 

  3. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300–8. https://doi.org/10.3748/wjg.14.4300.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncology. 2018;29(Suppl 4):iv238–55. https://doi.org/10.1093/annonc/mdy308.

    CAS  Article  Google Scholar 

  5. Australian product information, Lenvima® (Lenvatinib) hard capsule, https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01212-1&d=202005271016933. Accessed 25 May 2020.

  6. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.

    CAS  Article  PubMed  Google Scholar 

  7. Lenvatinib for untreated advanced hepatocellular carcinoma Technology appraisal guidance [TA551], National Institute for Health and Care Excellence UK. https://www.nice.org.uk/guidance/ta551. Accessed 12 Feb 2020.

  8. Pan-Canadian Oncology Drug Review. Final Economic Guidance Report Lenvatinib (Lenvima) for Hepatocellular Carcinoma. https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf. Accessed 27 Jul 2020.

  9. Lenvatinib Public Summary Document (PSD), November 2018. https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-11/Lenvatinib-psd-november-2018. Accessed 20 May 2020.

  10. 10-year survival for Liver cancer. Australian Institute of Health and Welfare 2019. Cancer in Australia 2019. Cancer series no.101.Cat. no. CAN 123. Canberra: AIHW. https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/10-year-relative-survival. Accessed 27 Jul 2020.

  11. Public summary document for Sorafenib tosylate, tablet, 200 mg (base), Nexavar®, July 2008. https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-07/pbac-psd-sorafenib-july08. Accessed 15 Oct 2020.

  12. Elbasha EH, Chhatwal J. Myths and misconceptions of within-cycle correction: a guide for modelers and decision makers. Pharmacoeconomics. 2016;34(1):13–22. https://doi.org/10.1007/s40273-015-0337-0.

    Article  PubMed  Google Scholar 

  13. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) Version 5.0. https://pbac.pbs.gov.au/. Accessed 3 Feb 2020.

  14. Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771–80. https://doi.org/10.1007/s40258-019-00513-3.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Regorafenib Public Summary Document. https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2018-11/Regorafenib-psd-november-2018. Accessed 7 Mar 2020.

  16. Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17(4):786–802.

    Article  Google Scholar 

  17. Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–54.

    Article  Google Scholar 

  18. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–90. https://doi.org/10.1038/sj.bjc.6603326.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, et al. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:655–68. https://doi.org/10.2147/CEOR.S136657.

    Article  PubMed  PubMed Central  Google Scholar 

  20. HealthCare Bayer. Single technology appraisal (STA) of sorafenib (Nexavar) for the treatment of hepatocellular carcinoma (HCC) [TA189]. London: National Institute for Health and Care Excellence; 2009.

    Google Scholar 

  21. Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MDJP. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421–6.

    Article  Google Scholar 

  22. Kim JJ, McFarlane T, Tully S, Wong WW. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost–utility analysis. Oncologist. 2020;25(3):e512.

    CAS  Article  Google Scholar 

  23. Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019;54(6):558–70. https://doi.org/10.1007/s00535-019-01554-0.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Hong TP et al. An Australian population-based study of the incidence and outcomes of hepatocellular carcinoma: the hepatomas of melbourne epidemiological research (homer) study. PhD Thesis. https://minerva-access.unimelb.edu.au/bitstream/handle/11343/225659/84082%20PhD%20-%20FInal%20Revised.pdf?sequence=3&isAllowed=y. Accessed 12 Feb 2020.

  25. Venkatesan S, Lamfers M, Leenstra S, Vulto AG. Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US. Gabi J. 2017;6(2):89–96. https://doi.org/10.5639/gabij.2017.0602.016.

    Article  Google Scholar 

  26. First New Brand Price Reductions. The pharmaceutical benefits scheme. Government of Australia. https://www.pbs.gov.au/info/industry/pricing/pbs-items/first-new-brand-price-reductions. Accessed 30 June 2020.

  27. Clemens S, Begum N, Harper C, Whitty JA, Scuffham PA. A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res. 2014;23(8):2375–81. https://doi.org/10.1007/s11136-014-0676-x.

    Article  PubMed  Google Scholar 

  28. Atezolizumab US FDA Approval. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma#:~:text=On%20May%2029%2C%202020%2C%20the,not%20received%20prior%20systemic%20therapy. Accessed 21 Jun 2020.

Download references

Acknowledgements

The authors would like to thank Sundeep Pathak for their assistance in proof-reading the final version of the manuscript and Mussab Fagery for collecting some cost inputs for the model.

Author information

Authors and Affiliations

  1. Centre for Applied Health Economics, Griffith University, Nathan, QLD, 4111, Australia

    Masnoon Saiyed, Joshua Byrnes, Paul Scuffham & Martin Downes

  2. Menzies Health Institute Queensland, Griffith University, Nathan, QLD, 4111, Australia

    Paul Scuffham

  3. School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, S1 4DA, UK

    Tushar Srivastava

Authors
  1. Masnoon Saiyed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua Byrnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tushar Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Scuffham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Downes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masnoon Saiyed.

Ethics declarations

Funding

No specific funding was received for this study.

Conflict of interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Ethics approval

Not applicable.

Informed consent

Not applicable.

Consent for publication

Not applicable.

Code availability

Not applicable.

Author's contribution

MS conceived the study and developed the model, undertook the analysis, and wrote up the manuscript; TS, JB, MD, and PS helped with model validation and results interpretation, and critically reviewed the manuscript before submission.

Data availability

The authors declare that all input data to parameterize the decision analytic model are available within the article and the OSM. The model can be re-built entirely based on the detailed description of the model structure in the “Method” section (Sect. 2) and information provided.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 818 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saiyed, M., Byrnes, J., Srivastava, T. et al. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clin Drug Investig 40, 1167–1176 (2020). https://doi.org/10.1007/s40261-020-00983-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-020-00983-7